Brainstorm Cell Therapeutics Inc. (BCLI)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
BCLI Insider Trading Activity
BCLI Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $283,114 | 13 | 93 |
Sells | $22,069 | 1 | 7 |
Related Transactions
| Lebovits Chaim | President & CEO | 13 | $283,114 | 0 | $0 | $283,114 |
| Dagher Ibrahim B. | Chief Medical Officer | 0 | $0 | 1 | $22,069 | $-22,069 |
About Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Insider Activity of Brainstorm Cell Therapeutics Inc.
Over the last 12 months, insiders at Brainstorm Cell Therapeutics Inc. have bought $283,114 and sold $22,069 worth of Brainstorm Cell Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Brainstorm Cell Therapeutics Inc. have bought $325,305 and sold $491,363 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lebovits Chaim (President & CEO) — $283,114.
The last purchase of 1,836 shares for transaction amount of $6,292 was made by Lebovits Chaim (President & CEO) on 2024‑10‑01.
List of Insider Buy and Sell Transactions, Brainstorm Cell Therapeutics Inc.
| 2024-10-01 | Lebovits Chaim | President & CEO | 1,836 0.031% | $3.43 | $6,292 | -44.46% | ||
| 2024-09-30 | Lebovits Chaim | President & CEO | 22,000 0.0247% | $0.23 | $5,016 | -47.68% | ||
| 2024-07-19 | Sale | Dagher Ibrahim B. | Chief Medical Officer | 63,000 0.0801% | $0.35 | $22,069 | -60.89% | |
| 2024-05-28 | Lebovits Chaim | President & CEO | 15,000 0.0215% | $0.52 | $7,775 | -71.48% | ||
| 2024-05-22 | Lebovits Chaim | President & CEO | 25,000 0.0399% | $0.64 | $16,000 | -74.01% | ||
| 2024-05-21 | Lebovits Chaim | President & CEO | 25,000 0.0333% | $0.58 | $14,475 | -76.02% | ||
| 2024-05-13 | Lebovits Chaim | President & CEO | 10,000 0.0131% | $0.49 | $4,900 | -72.51% | ||
| 2024-05-11 | Lebovits Chaim | President & CEO | 10,000 0.015% | $0.47 | $4,665 | -20.07% | ||
| 2024-05-10 | Lebovits Chaim | President & CEO | 20,000 0.0298% | $0.47 | $9,300 | -66.81% | ||
| 2024-05-07 | Lebovits Chaim | President & CEO | 66,300 0.0971% | $0.37 | $24,816 | -58.61% | ||
| 2024-05-06 | Lebovits Chaim | President & CEO | 135,000 0.1982% | $0.38 | $50,666 | -59.18% | ||
| 2024-04-19 | Lebovits Chaim | President & CEO | 15,000 0.0214% | $0.52 | $7,799 | -69.92% | ||
| 2024-04-18 | Lebovits Chaim | President & CEO | 115,072 0.172% | $0.53 | $60,470 | -68.48% | ||
| 2024-04-17 | Lebovits Chaim | President & CEO | 130,000 0.1919% | $0.55 | $70,941 | -69.91% | ||
| 2023-09-01 | Lindborg Stacy | Co-Chief Executive Officer | 11,500 0.0277% | $1.77 | $20,402 | -78.57% | ||
| 2020-07-16 | Sale | ACC International Holdings Ltd. | 7,823 0.0252% | $13.47 | $105,351 | -62.10% | ||
| 2020-07-16 | Setboun David | EVP and COO | 5,000 0.0155% | $12.95 | $64,740 | -62.10% | ||
| 2020-07-15 | Sale | ACC International Holdings Ltd. | 18,430 0.06% | $13.12 | $241,715 | -60.36% | ||
| 2020-07-15 | Abbhi Sankesh | director | 46,779 0.1507% | $12.99 | $607,659 | -60.36% | ||
| 2020-07-13 | Sale | ACC International Holdings Ltd. | 40,000 0.1354% | $13.52 | $540,952 | -59.56% |
Insider Historical Profitability
| Lebovits Chaim | President & CEO | 80960 1.4195% | $109,296.00 | 13 | 0 | |
| Dagher Ibrahim B. | Chief Medical Officer | 0 0% | $0 | 0 | 1 | |
| ACCBT Corp. | 10 percent owner | 7075000 124.0482% | $9.55M | 5 | 0 | |
| Abbhi Sankesh | director | 2164530 37.9514% | $2.92M | 1 | 0 | |
| Javitt Jonathan C | director | 460000 8.0653% | $621,000.00 | 0 | 9 | |
| Lindborg Stacy | Co-Chief Executive Officer | 181500 3.1823% | $245,025.00 | 1 | 0 | <0.0001% |
| ARBEL IRIT | director | 155833 2.7323% | $210,374.55 | 1 | 1 | <0.0001% |
| FRANKENBERGER MIKE | 155000 2.7177% | $209,250.00 | 3 | 2 | ||
| STOLICK DAVID | Chief Financial Officer | 150000 2.63% | $202,500.00 | 0 | 4 | |
| Kern Ralph Dr. | COO and Chief Medical Officer | 115655 2.0278% | $156,134.25 | 2 | 0 | +9.06% |
| ACC International Holdings Ltd. | 67053 1.1757% | $90,521.55 | 14 | 5 | <0.0001% | |
| Setboun David | EVP and COO | 55000 0.9643% | $74,250.00 | 1 | 0 | |
| Bibring Yoram | Chief Financial Officer | 50000 0.8767% | $67,500.00 | 2 | 0 | <0.0001% |
| Shah Preetam | EVP, CFO and Treasurer | 36600 0.6417% | $49,410.00 | 1 | 0 | |
| SHORR ROBERT G L | director | 28399 0.4979% | $38,338.65 | 0 | 13 | |
| TAUB MALCOLM S | director | 8666 0.1519% | $11,699.10 | 0 | 22 | |
| Araya Arturo | Chief Commercial Officer | 8608 0.1509% | $11,620.80 | 1 | 0 | |
| Yablonka Uri | EVP & Chief Business Officer | 7543 0.1323% | $10,183.05 | 1 | 0 | <0.0001% |
| Almenoff June Sherie | director | 7175 0.1258% | $9,686.25 | 2 | 0 | +12.25% |
| Fiorino Anthony S. | Chief Executive Officer | 2500 0.0438% | $3,375.00 | 4 | 0 | <0.0001% |
| Friedman Mordechai | director | 0 0% | $0 | 0 | 1 |
Historical Insider Profitability vs. Competitors
$18,881,323 | 88 | -48.96% | $7.26M | |
$1,241,605 | 44 | -21.46% | $8.79M | |
$523,320 | 24 | 94.37% | $7.6M | |
Brainstorm Cell Therapeutics Inc. (BCLI) | $746,223 | 23 | -7.24% | $7.7M |
$31,129 | 22 | -11.96% | $5.92M | |
$86,569,038 | 18 | -12.64% | $10.06M | |
$1,080,165 | 17 | -6.62% | $7.93M | |
$51,865 | 17 | -38.70% | $6.26M | |
$490,284 | 15 | -19.03% | $9.38M | |
$1,199,157 | 14 | 7.52% | $8.99M | |
$8,971,546 | 8 | 6.18% | $7.07M | |
$149,611 | 4 | -25.43% | $9.34M | |
$76,299 | 4 | 11.60% | $5.83M | |
$14,530 | 3 | 62.23% | $7.16M | |
$4,423 | 2 | 3.27% | $5.6M | |
$45,452 | 2 | -43.10% | $6.93M | |
$7,699,992 | 2 | -74.95% | $9.43M | |
$1,049,630 | 1 | -74.91% | $7.71M | |
$25,173 | 1 | -68.88% | $9.06M |
BCLI Institutional Investors: Active Positions
| Increased Positions | 19 | +29.23% | 216,936 | +24.64% |
| Decreased Positions | 31 | -47.69% | 677,890 | -77% |
| New Positions | 14 | New | 185,836 | New |
| Sold Out Positions | 17 | Sold Out | 641,283 | Sold Out |
| Total Postitions | 53 | -18.46% | 419,391 | -52.36% |
BCLI Ownership Change vs Market
Institutional Investor Ownership
| Caldwell Sutter Capital, Inc. | $221.00 | 2.62% | 157,009 | +157,009 | New | 2024-12-31 |
| Vanguard Group Inc | $111.00 | 1.31% | 78,441 | -22,273 | -22.11% | 2024-12-31 |
| Geode Capital Management, Llc | $74.00 | 0.88% | 52,501 | +6,978 | +15.33% | 2024-12-31 |
| Blackrock, Inc. | $35.00 | 0.42% | 25,172 | -3 | -0.01% | 2024-12-31 |
| Liberty Wealth Management Llc | $32.00 | 0.38% | 22,666 | -12 | -0.05% | 2024-12-31 |
| Hrt Financial Lp | $28.00 | 0.33% | 20,022 | +20,022 | New | 2024-12-31 |
| Weaver Consulting Group | $22.00 | 0.26% | 15,623 | -2 | -0.01% | 2024-12-31 |
| Two Sigma Securities, Llc | $16.00 | 0.19% | 11,300 | +9,980 | +756.06% | 2024-12-31 |
| Osaic Holdings, Inc. | $15.00 | 0.18% | 10,519 | +9,818 | +1,400.57% | 2024-12-31 |
| Raymond James & Associates | $9.00 | 0.11% | 6,344 | -1,075 | -14.49% | 2024-09-30 |